768 related articles for article (PubMed ID: 31779619)
1. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
[TBL] [Abstract][Full Text] [Related]
2. Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits.
Zhang X; Zhang Z; Zhao Y; Jiang N; Qiu J; Yang Y; Li J; Liang X; Wang X; Tse G; Li G; Liu T
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28507060
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Yurista SR; Silljé HHW; Rienstra M; de Boer RA; Westenbrink BD
Cardiovasc Diabetol; 2020 Jan; 19(1):5. PubMed ID: 31910841
[TBL] [Abstract][Full Text] [Related]
4. β3-Adrenoceptor Impairs Mitochondrial Biogenesis and Energy Metabolism During Rapid Atrial Pacing-Induced Atrial Fibrillation.
Dong J; Zhao J; Zhang M; Liu G; Wang X; Liu Y; Yang N; Liu Y; Zhao G; Sun J; Tian J; Cheng C; Wei L; Li Y; Li W
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):114-26. PubMed ID: 26130614
[TBL] [Abstract][Full Text] [Related]
5. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
6. Wenxin Keli Regulates Mitochondrial Oxidative Stress and Homeostasis and Improves Atrial Remodeling in Diabetic Rats.
Gong M; Yuan M; Meng L; Zhang Z; Tse G; Zhao Y; Zhang Y; Yuan M; Liang X; Fan G; Yan GX; Li G; Liu T
Oxid Med Cell Longev; 2020; 2020():2468031. PubMed ID: 32104528
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Luippold G; Klein T; Mark M; Grempler R
Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
9. Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
Bode D; Semmler L; Wakula P; Hegemann N; Primessnig U; Beindorff N; Powell D; Dahmen R; Ruetten H; Oeing C; Alogna A; Messroghli D; Pieske BM; Heinzel FR; Hohendanner F
Cardiovasc Diabetol; 2021 Jan; 20(1):7. PubMed ID: 33413413
[TBL] [Abstract][Full Text] [Related]
10. Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits.
Fu H; Li G; Liu C; Li J; Wang X; Cheng L; Liu T
J Cardiovasc Electrophysiol; 2015 Feb; 26(2):211-22. PubMed ID: 25199622
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
Liu C; Liu R; Fu H; Li J; Wang X; Cheng L; Korantzopoulos P; Tse G; Li G; Liu T
Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28665544
[TBL] [Abstract][Full Text] [Related]
13. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.
Liu T; Zhao H; Li J; Korantzopoulos P; Li G
Cardiovasc Ther; 2014 Aug; 32(4):178-83. PubMed ID: 24814361
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats.
Koizumi T; Watanabe M; Yokota T; Tsuda M; Handa H; Koya J; Nishino K; Tatsuta D; Natsui H; Kadosaka T; Koya T; Nakao M; Hagiwara H; Kamada R; Temma T; Tanaka S; Anzai T
Front Cardiovasc Med; 2023; 10():1005408. PubMed ID: 36815024
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
Belosludtsev KN; Starinets VS; Belosludtsev MN; Mikheeva IB; Dubinin MV; Belosludtseva NV
Mitochondrion; 2021 Jul; 59():246-254. PubMed ID: 34144205
[TBL] [Abstract][Full Text] [Related]
18. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
19. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.
Makrecka-Kuka M; Korzh S; Videja M; Vilks K; Cirule H; Kuka J; Dambrova M; Liepinsh E
Cardiovasc Drugs Ther; 2020 Dec; 34(6):791-797. PubMed ID: 32424653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
